Martinsynge Pharma Sciences Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
- Paid Up Capital ₹ 8.00 M
- Company Age 9 Year, 9 Months
- Last Filing with ROC 31 Mar 2021
- Revenue Growth -40.99%
- Profit Growth 169.65%
- Ebitda 76.48%
- Net Worth 1.77%
- Total Assets -13.42%
About Martinsynge Pharma Sciences
Martinsynge Pharma Sciences Private Limited (MPSPL) is a Private Limited Indian Non-Government Company incorporated in India on 17 April 2015 (Nine years and nine months 18 days old ). Its registered office is in Hyderabad, Telangana, India.
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2021. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 8.00 M, as per Ministry of Corporate Affairs (MCA) records.
Swathi Gandra, Swarna Goli, and Venkata Goli serve as directors at the Company.
Company Details
-
Location
Hyderabad, Telangana, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media
Corporate Identity Details
-
CIN/LLPIN
U74900TG2015PTC098547
-
Company No.
098547
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
17 Apr 2015
-
Date of AGM
30 Sep 2021
-
Date of Balance Sheet
31 Mar 2021
-
Listing Status
Unlisted
-
ROC Code
Roc Hyderabad
Industry
Who are the key members and board of directors at Martinsynge Pharma Sciences?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Swathi Gandra
|
Director | 29-Oct-2018 | Current |
|
Swarna Goli
|
Director | 29-Oct-2018 | Current |
|
Venkata Goli
|
Director | 29-Oct-2018 | Current |
Financial Performance of Martinsynge Pharma Sciences.
Martinsynge Pharma Sciences Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 40.99% decrease. The company also saw a substantial improvement in profitability, with a 169.65% increase in profit. The company's net worth moved up by a moderate rise of 1.77%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Martinsynge Pharma Sciences?
In 2021, Martinsynge Pharma Sciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Ramis Laboratories Private LimitedVenkata Goli is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Martinsynge Pharma Sciences?
Unlock and access historical data on people associated with Martinsynge Pharma Sciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Martinsynge Pharma Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Martinsynge Pharma Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
